Stifel Nicolaus Has Lowered Expectations for Insmed (NASDAQ:INSM) Stock Price

Insmed (NASDAQ:INSM) had its target price trimmed by Stifel Nicolaus from $97.00 to $96.00 in a report published on Friday,Benzinga reports. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

Other equities research analysts have also issued reports about the company. Guggenheim upped their price target on Insmed from $95.00 to $101.00 and gave the company a “buy” rating in a research report on Friday, February 7th. Cantor Fitzgerald reissued an “overweight” rating on shares of Insmed in a report on Wednesday. Wells Fargo & Company increased their target price on shares of Insmed from $85.00 to $107.00 and gave the stock an “overweight” rating in a report on Wednesday. JPMorgan Chase & Co. increased their price objective on shares of Insmed from $83.00 to $92.00 and gave the stock an “overweight” rating in a research note on Friday, February 7th. Finally, Truist Financial reiterated a “buy” rating and set a $105.00 price objective (up previously from $100.00) on shares of Insmed in a research note on Friday, November 1st. One equities research analyst has rated the stock with a sell rating and fifteen have given a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $91.00.

Insmed Trading Down 3.0 %

INSM opened at $81.06 on Friday. The stock has a market capitalization of $14.50 billion, a PE ratio of -14.61 and a beta of 1.11. The firm’s fifty day moving average price is $74.29 and its 200 day moving average price is $73.59. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99. Insmed has a 12-month low of $21.92 and a 12-month high of $84.91.

Insmed (NASDAQ:INSM) last issued its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.15). The firm had revenue of $104.44 million for the quarter, compared to analyst estimates of $102.31 million. As a group, research analysts expect that Insmed will post -5.42 EPS for the current fiscal year.

Insider Activity

In related news, CFO Sara Bonstein sold 18,322 shares of the firm’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $80.31, for a total transaction of $1,471,439.82. Following the transaction, the chief financial officer now owns 118,863 shares in the company, valued at $9,545,887.53. This trade represents a 13.36 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO William Lewis sold 18,750 shares of Insmed stock in a transaction on Thursday, December 19th. The shares were sold at an average price of $69.91, for a total value of $1,310,812.50. Following the transaction, the chief executive officer now owns 384,960 shares in the company, valued at approximately $26,912,553.60. This trade represents a 4.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 532,207 shares of company stock valued at $41,400,465. Company insiders own 4.60% of the company’s stock.

Hedge Funds Weigh In On Insmed

Several hedge funds have recently modified their holdings of the company. National Bank of Canada FI grew its holdings in Insmed by 9.7% during the fourth quarter. National Bank of Canada FI now owns 1,668 shares of the biopharmaceutical company’s stock worth $115,000 after acquiring an additional 147 shares during the period. CIBC Asset Management Inc grew its stake in shares of Insmed by 3.5% in the 3rd quarter. CIBC Asset Management Inc now owns 4,438 shares of the biopharmaceutical company’s stock worth $324,000 after purchasing an additional 149 shares during the last quarter. Abel Hall LLC grew its stake in shares of Insmed by 4.7% in the 4th quarter. Abel Hall LLC now owns 3,333 shares of the biopharmaceutical company’s stock worth $230,000 after purchasing an additional 151 shares during the last quarter. Snowden Capital Advisors LLC grew its stake in shares of Insmed by 2.5% in the 4th quarter. Snowden Capital Advisors LLC now owns 6,602 shares of the biopharmaceutical company’s stock worth $456,000 after purchasing an additional 158 shares during the last quarter. Finally, Commerce Bank grew its position in Insmed by 2.4% in the third quarter. Commerce Bank now owns 6,833 shares of the biopharmaceutical company’s stock worth $499,000 after buying an additional 163 shares during the last quarter.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.